Seeking Alpha
Long/short equity, insider ownership
Profile| Send Message|
( followers)  

Summary

  • 3 insiders purchased BioAmber stock within one month.
  • The stock was sold by no insiders in the month of intensive purchasing.
  • All 3 of these insiders increased their holdings by more than 10% each.

BioAmber (NYSE:BIOA) produces and sells bio-succinic acid to customers in various chemical markets in the United States.

(click to enlarge)

Insider buying during the last 30 days

Here is a table of BioAmber's insider activity during the last 30 days.

NameTitleTrade DateShares PurchasedCurrent OwnershipIncrease In Shares
Jean-Francois HucCEOMay 123,00020,345 shares+17.3%
Michael HartmannEVPMay 122,50021,220 shares+13.4%
Andrew AshworthCFOMay 123,0003,000 sharesfrom 0 to 3,000

There have been 8,500 shares purchased by insiders during the last 30 days.

Insider buying by calendar month

Here is a table of BioAmber's insider activity by calendar month.

MonthInsider buying / sharesInsider selling / shares
May 20148,5000
April 201400
March 201400
February 201400
January 201400
December 201300
November 20137,2000
October 201300
September 20131,7000
August 201318,3000
July 201300
June 201300
May 201300

There have been 35,700 shares purchased and there have been zero shares sold by insiders since May 2013. BioAmber had its IPO in May 2013.

Financials

BioAmber reported the first-quarter financial results on May 8 with the following highlights:

Revenue$351,000
Net loss$19.9 million
Adjusted net loss$8.3 million
Cash$73.0 million
Debt$30.0 million

The three insiders purchased their shares after these results.

Outlook

BioAmber expects to have its Sarnia plant completed in early 2015.

Competition

BioAmber's competitors include Koninklijke DSM N.V. (OTCQX:RDSMY) and BASF SE (OTCQX:BASFY). Here is a table comparing these companies.

CompanyBIOARDSMYBASFY
Market Cap:185.22M12.27B104.80B
Employees:5421,189112,305
Qtrly Rev Growth (yoy):0.060.00-0.01
Revenue:2.69M12.46B102.08B
Gross Margin:-0.030.280.25
EBITDA:-28.96M1.59B13.34B
Operating Margin:-11.040.070.09
Net Income:-43.63M262.70M6.75B
EPS:-2.470.447.34
P/E:N/A40.3815.54
PEG (5 yr expected):N/A2.389.00
P/S:68.560.991.03

BioAmber is still building its Sarnia plant.

Conclusion

There have been three different insiders buying BioAmber, and there have not been any insiders selling BioAmber during the last 30 days. All three of these insiders increased their holdings by more than 10% each.

The three insiders purchased their shares at prices ranging from $10.00 to $10.17. I believe BioAmber could be a good pick below $10.17 based on the intensive insider buying.

Editor's Note: This article discusses one or more securities that do not trade on a major exchange. Please be aware of the risks associated with these stocks.

Source: BioAmber: 3 Different Insiders Have Purchased Shares This Month